Skip to main content

CRO India for US Sponsors

  • Home
  • CRO India for US Sponsors

Clinical research, regulatory and compliance information from BioAgile Therapeutics.

Need Expert Help? We’re Just a Call Away.

In short: A US sponsor can use clinical data generated in India to support an IND or a marketing application, provided the study followed good clinical practice (GCP), including independent ethics committee review and documented informed consent, and FDA is able to verify the data by on-site inspection if it asks to. BioAgile Therapeutics is a CDSCO-approved, ISO 9001:2015 certified CRO in Bengaluru whose work follows ICH-GCP principles.

Can FDA accept clinical data from India?

Yes. The rule is 21 CFR 312.120, “Foreign clinical studies not conducted under an IND”. It says FDA will accept a well-designed and well-conducted foreign study as support for an IND or a marketing application when two conditions are met:

  • The study was conducted in accordance with GCP. For this purpose GCP includes review and approval, or a favourable opinion, by an independent ethics committee before the study starts, continuing review during the study, and freely given informed consent documented before enrolment.
  • FDA is able to validate the data through an on-site inspection if it considers that necessary.

The sponsor must also describe to FDA the steps it took to make sure the research followed GCP. FDA’s own question-and-answer guidance on this rule is listed at the end of this page. The location of the study site is not the test. Compliance, documentation and inspectability are.

What FDA looks for in a foreign study

Ethics and consent

Protocol and consent form approved by a registered ethics committee before the first subject is enrolled. Consent documented for every subject, with versions controlled.

Source data you can show

Source documents, case report forms and audit trails that agree with each other, so a reviewer can follow any data point back to where it began.

Electronic records

Where a study uses electronic systems, FDA’s question-and-answer guidance on electronic records and signatures in clinical investigations covers validation, audit trails and metadata, and the records needed to reconstruct a study (linked below). Our data management team plans for those points.

Open to inspection

Site, sponsor and CRO records are kept organised and retrievable, and the team is prepared to host an inspector. FDA runs clinical inspections for bioavailability and bioequivalence studies as well as for clinical trials.

How we support US sponsors

NeedWhat BioAgile does
BA/BE studies for genericsDesign, conduct, bioanalytical coordination, biostatistics and the study report. See BA/BE studies.
Phase I to IV clinical trialsProject management, site and investigator coordination, monitoring and safety reporting. See clinical trials.
Indian regulatory stepsCDSCO submissions and ethics committee approvals under the New Drugs and Clinical Trials Rules, 2019. See regulatory support.
Data and statisticsData management and biostatistics to a plan agreed with you in advance. See data management and biostatistics.
Documents for submissionProtocols, clinical study reports and regulatory summaries. See medical writing.
QualityAudits and SOP-driven quality assurance. See clinical quality assurance.

Running a study in India for a US programme

An Indian study has two regulatory layers. The Indian layer is CDSCO permission and ethics committee approval, which we manage. The US layer is what FDA needs to see in your submission. We plan both from the start so the Indian approvals, the protocol and the documentation do not have to be reworked later. Our overview page, CRO in India, covers the Indian framework in detail.

Indian working hours overlap well with the European working day and reach the early morning on the US East Coast. We agree a regular call schedule and a single named project manager at kick-off.

BioAgile is registered with CDSCO as a CRO (Reg. No. CRO/KA/2026/000173) and holds ISO 9001:2015 certification. We do not claim an FDA inspection history on this page. If a specific inspection record matters to your decision, ask us and we will tell you what we can document.

Frequently asked questions

Does FDA accept clinical trial data generated in India?

FDA accepts data from a well-designed, well-conducted foreign study if it followed GCP, including ethics committee review and informed consent, and if FDA can validate the data by inspection when needed (21 CFR 312.120).

Do I need an IND for a study run only in India?

Not necessarily. 21 CFR 312.120 covers foreign studies not conducted under an IND, if they meet its conditions. Whether an IND is the right route for your programme is a regulatory decision to take with your US regulatory advisers.

What does the sponsor have to tell FDA about the study?

The sponsor must describe the actions taken to make sure the research conformed to GCP. We help prepare the study documents that support that description.

Can BioAgile run BA/BE studies for generic drug applications?

Yes. BA/BE studies are one of our core services. Which study design your application needs is set by the reference product and your US regulatory strategy, and we plan it with you.

Are your electronic systems compliant with US expectations?

FDA’s guidance on electronic records in clinical investigations covers validation, audit trails and metadata. Tell us which systems your protocol relies on and we will confirm what is in place before the study starts.

Who is the CRO regulated by in India?

Indian clinical trials are regulated by CDSCO under the New Drugs and Clinical Trials Rules, 2019. BioAgile is CDSCO-registered as a CRO.

Official sources

Planning a study in India for a US programme?

Tell us the product, the study type and your target submission. We will reply with a feasible plan and the questions we would need answered.

Contact our teamCall 080 4375 4520